Key result
Adding evolocumab to statins is cost-effective in ASCVD patients with LDL-C above /dL.
Answers are grounded in this paper and cite their sources.
Objective: The aim of this work was to evaluate the cost-effectiveness of evolocumab in addition to standard statin therapy with or without ezetimibe in the treatment of patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) with levels of LDL-C above 100 mg/dL. Method: A theoretical cohort of patients was forecast by a Markov model that includes 11 health states for a lifetime horizon. In the base-case, the standard therapy was characterized by statins with or without ezetimibe. Two sub-populations have been considered, Recent MI (Myocardial Infarction in the last year) and Multiple events (population with multiple MI). The results were also presented for a subset of the Multiple events populations consisting of patients who have experienced a myocardial infarction (MI) in the last year. Results: For the Recent MI and Multiple events populations, ICER values of € 39,547 and € 35,744 respectively were estimated. The value of ICER was lower for the Multiple events with MI < 1 year population (€ 29,949). Considering statins with ezetimibe as standard therapy, ICER values were found to be equal to € 39,781, € 35,986 and € 30,190 respectively for the populations Recent MI, Multiple events and Multiple events with MI < 1 year. Conclusions: The estimated ICER values for the Recent MI, Multiple events and Multiple events populations with MI < 1 year were below the cost-effectiveness threshold of € 40,000, suggesting therefore how the treatment with evolocumab in addition to the standard therapy can be a cost-effective treatment both compared to standard therapy with statins and standard therapy with statins + ezetimibe.
No takes yet. Share an insight, caveat, or question.
Marcellusi et al. (2021) studied Clinically evident atherosclerotic cardiovascular disease (ASCVD). Evolocumab plus standard statin therapy (with or without ezetimibe) vs. Standard statin therapy with or without ezetimibe was evaluated on Incremental cost-effectiveness ratio (ICER) (ICER €39,547 (Recent MI), €35,744 (Multiple events), €29,949 (Multiple events with MI <1 year)). Evolocumab added to standard statin therapy was cost-effective in ASCVD patients with LDL-C >/dL, yielding ICERs of €29,949 to €39,781 (below the €40,000 threshold).
Synapse has enriched 10 related papers. Consider them for comparative context: